In SCAN-B, FMO2 was upregulated in ER-, PR-, and ER-/PR- breast cancer (P < 0.0001, = 0.0006, and < 0.0001, respectively) (Supplementary Figure 1A–1C and Supplementary Table 1), which was consistent with TCGA. This evidence concerns the gene FMO2 and breast cancer.